Venaxis Files for Public Offering, Targets $18.4M in Net Proceeds | GenomeWeb

NEW YORK (GenomeWeb News) – Venaxis today priced the public offering of about 8.3 million shares of its common stock at $2.40 per share.

Net proceeds from the offering are expected at around $18.4 million, which the Castle Rock, Colo.-based firm will use for working capital and other corporate purposes, including the sales and marketing of its APPY1 appendicitis test in the European Union, and development efforts to expand and improve the test's performance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.